Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2RR0Bsx
via IFTTT